Results 221 to 230 of about 36,345 (262)
Some of the next articles are maybe not open access.
Overcoming castration resistance in prostate cancer
Current Opinion in Urology, 2012Recent advances in our understanding of the androgen axis signaling pathway have led to the development of therapeutic strategies to overcome the state of 'castration resistance' in prostate cancer. In this review, we examine the mechanisms of castration resistance, as well as recently reported and ongoing clinical studies, which will further identify ...
Che-Kai, Tsao +3 more
openaire +2 more sources
Immunotherapy for Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2012The improved survival with sipuleucel-T, an autologous antigen-presenting cell-based agent, for the treatment of patients with metastatic asymptomatic and minimally symptomatic castration-resistant prostate cancer supports immunotherapy as a valid approach. Also, multiple novel immunotherapeutic approaches are undergoing vigorous investigation.
Guru, Sonpavde, Philip W, Kantoff
openaire +2 more sources
New developments in castrate‐resistant prostate cancer
BJU International, 2012Castrate‐resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease.
Shore, N., Mason, M., de Reijke, Th M.
openaire +2 more sources
Resistance to Castration – Resistance to Drugs
2013Up to 70 % of newly diagnosed patients with advanced prostate cancer (PCa) will progress to castration-resistant prostate cancer (CRPC) and, in most cases (from 50 to 70 %), will develop hematogenous bone metastasis. Once PCa cells spread to the skeleton, cancer-related death becomes inevitable, with a death burden of more than 28,000 cases in 2012, in
openaire +2 more sources
Castration-Resistant Prostate Cancer
Urologic Clinics of North America, 2017Men with advanced prostate cancer are typically treated with hormonal therapy, which results in tumor shrinkage. However, tumors relapse and develop into a highly aggressive and lethal form of the disease, termed castration-resistant prostate cancer (CRPC).
Kelly Stratton, Michael Cookson
openaire +2 more sources
Emerging therapies in castrate-resistant prostate cancer
Current Opinion in Oncology, 2009Prostate cancer continues to represent a major health problem. It represents the most common cancer in US men, with an estimated 186 320 new cases diagnosed in 2008. It is the second leading cause of cancer death in men in the United States. Despite several attempts, the median survival for men with metastatic castrate-resistant prostate cancer is 1-2 ...
Kiran, Lassi, Nancy A, Dawson
openaire +2 more sources
The Molecular Evolution of Castration-resistant Prostate Cancer
European Urology Focus, 2016Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cancer. However, castration-resistant prostate cancer (CRPC) nearly invariably develops through a range of different molecular mechanisms accompanied by progression to a more aggressive phenotype.To understand the key molecular mechanisms leading to CRPC and the ...
Yvonne, Ceder +5 more
openaire +2 more sources
Satraplatin for the Therapy of Castration-Resistant Prostate Cancer
Future Oncology, 2009While docetaxel-based chemotherapy improves survival in patients with castration-resistant prostate cancer, all of these patient's cancers will eventually progress and other active treatment agents are necessary. Satraplatin is a third-generation orally-available platinum analog that demonstrated a 33% reduction in the risk of progression in patients ...
Guru, Sonpavde, Cora N, Sternberg
openaire +2 more sources
Leading causes of castration-resistant prostate cancer
Expert Review of Anticancer Therapy, 2015Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Androgen receptor has a key role in the initiation and progression of PCa. Currently, androgen deprivation therapy is the standard treatment for PCa patients due to its effective suppression of androgen receptor signaling.
Mingqian, Lu, Hongda, Lu, Qingzhi, Kong
openaire +2 more sources
Enzalutamide in Castration-Resistant Prostate Cancer
New England Journal of Medicine, 2018Giacomo, Bregni +2 more
openaire +4 more sources